Poseida Therapeutics (PSTX) Status Update summary

Platform Technology and Pipeline Overview

• Proprietary non-viral genetic engineering tools, including transposon-based gene insertion and Cas-CLOVER editing, enable a robust allogeneic CAR-T and in vivo gene therapy pipeline focused on TSCM-rich products for oncology and autoimmune diseases.

• In-house GMP manufacturing in La Jolla delivers high-yield, consistent, and scalable production, supported by Booster Molecule technology and a rigorous donor screening program, with future enhancements using AI and bioreactor technologies.

• The pipeline includes clinical and preclinical programs targeting hematologic malignancies, solid tumors, and autoimmune diseases, with several assets advancing toward IND filings and ongoing trials.

• Partnerships with Roche and Astellas provide funding, technology validation, and collaborative development, especially in hematology and solid tumors, with deals valued up to $6 billion and over $400 million generated in external payments in three years.

• The platform enables rapid, broad patient access, with allogeneic CAR-T products offering off-the-shelf, outpatient treatment and broad patient reach.

Clinical and Preclinical Program Highlights

• P-BCMA-ALLO1, partnered with Roche, shows a 91% response rate in phase 1b for relapsed/refractory multiple myeloma, including high efficacy in BCMA-experienced patients, with favorable safety and rapid time to response.

• Dual CAR programs (P-CD19CD20-ALLO1, P-BCMA-CD19-ALLO1) target B-cell malignancies and autoimmune diseases, demonstrating robust preclinical and early clinical activity, with IND-enabling studies ongoing.

• P-CD70-ALLO1 targets AML and RCC, leveraging shRNA knockdown for potency and safety, with robust preclinical anti-tumor activity and minimal off-target effects.

• Solid tumor programs include P-MUC1C-ALLO1 (phase 1, data update at ESMO IO), P-PSMA-ALLO1 (preclinical), and ConvertibleCAR collaborations with Astellas, all leveraging multi-antigen and armoring strategies.

• Clinical milestones include ongoing and planned trials for P-BCMA-ALLO1, P-CD19CD20-ALLO1, and P-MUC1C-ALLO1, with key data updates expected in 2024 and 2025.

Manufacturing, Technology, and Competitive Advantages

• Fully integrated, self-reliant GMP manufacturing enables rapid, cost-effective, and scalable production, with up to 100 doses per donor batch and consistent quality.

• Proprietary Booster Molecule technology and non-viral platform allow for high TSCM content, multi-gene engineering, and embedded safety switches, protected by a strong IP estate.

• Donor screening and selection optimize consistency, yield, and potency, with AI and bioreactor technologies under evaluation for future improvements.

• Allogeneic CAR-T products offer rapid, off-the-shelf treatment, outpatient administration, and broad patient access, addressing limitations of autologous therapies.

• Strategic partnerships and a focus on wholly owned assets drive value creation and support expansion into new indications and geographies.